Literature DB >> 10611125

Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis.

G Wolswijk1.   

Abstract

One of the hallmarks of the human demyelinating disease multiple sclerosis is the inability to compensate adequately for the loss of myelin and of oligodendrocytes, the myelin-forming cells of the CNS. Oligodendrocyte precursor cells, a potential source of oligodendrocytes, have been identified in lesions of chronic multiple sclerosis, but it is not known whether they develop into new, fully differentiated oligodendrocytes, capable of remyelination. Sections of post-mortem multiple sclerosis tissue were therefore immunolabelled with antibodies to galactocerebroside (GalC), the first oligodendrocyte-specific molecule to be expressed by differentiating oligodendrocyte precursor cells, and myelin oligodendrocyte glycoprotein (MOG), a marker for mature oligodendrocytes. In total, 23 lesions from 15 subjects with chronic progressive multiple sclerosis were analysed. The immunolabelling revealed that chronic multiple sclerosis lesions contain only small numbers of immature, process-bearing, GalC-positive oligodendrocytes (0-2 cells/mm(2) in 10 micrometer thick sections); they had a relatively large, pale nucleus (maximum diameter: 9.9 +/- 0.9 micrometer). Although they appeared to make contact with surrounding demyelinated axons, most immature oligodendrocytes appeared not to be engaged in myelination. These findings suggest that oligodendrocyte differentiation of precursor cells is a rare event in chronic multiple sclerosis, which is consistent with the general failure of myelin repair during the later stages of this disease. The lesions in the collection, in particular those with recent demyelinating activity, contained another distinct population of oligodendrocytes. It consisted of small, round cells with a small, dense nucleus (maximum diameter: 6.8 +/- 0.8 micrometer) that expressed both GalC and MOG but lacked processes, suggesting that these cells were mature oligodendrocytes that had survived the loss of their myelin sheaths, i.e. they were demyelinated oligodendrocytes. In the most recent lesions in the collection, the demyelinated oligodendrocytes were found in large numbers throughout the centre of the lesion (up to 700 cells/mm(2)), while in the older lesions they were found only at the edges. Moreover, when the borders of these older lesions still contained numerous macrophages, they tended to contain more demyelinated oligodendrocytes than those lacking macrophages. These findings suggest that mature, demyelinated oligodendrocytes gradually disappear from lesion areas with increasing age of the lesion. The present study thus suggests that the failure of myelin repair in at least some cases of chronic multiple sclerosis is due to (i) the loss of demyelinated oligodendrocytes from lesion areas and (ii) the failure of the oligodendrocyte precursor population to expand and generate new oligodendrocytes. Gaining further insight into these processes may prove crucial for the development of remyelination promoting strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10611125     DOI: 10.1093/brain/123.1.105

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  51 in total

1.  Mechanisms Involved in the Remyelinating Effect of Sildenafil.

Authors:  Daniela Díaz-Lucena; María Gutierrez-Mecinas; Beatriz Moreno; José Lupicinio Martínez-Sánchez; Paula Pifarré; Agustina García
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-03       Impact factor: 4.147

Review 2.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

4.  Gene regulation networks related to neural differentiation of hESC.

Authors:  Jiang F Zhong; Yahui Song; Jing Du; Christine Gamache; Kathleen A Burke; Brett T Lund; Leslie P Weiner
Journal:  Gene Expr       Date:  2007

Review 5.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 6.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

7.  Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS.

Authors:  Regina C Armstrong
Journal:  Future Neurol       Date:  2007-11

8.  Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Authors:  Adam C Vana; Nicole C Flint; Norah E Harwood; Tuan Q Le; Marcus Fruttiger; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

9.  Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder.

Authors:  Christa Hercher; Vikramjit Chopra; Clare L Beasley
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

10.  Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies.

Authors:  Masafumi Ihara; Tuomo M Polvikoski; Ros Hall; Janet Y Slade; Robert H Perry; Arthur E Oakley; Elisabet Englund; John T O'Brien; Paul G Ince; Raj N Kalaria
Journal:  Acta Neuropathol       Date:  2010-01-21       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.